Thymoglobulin anti-thymocyte globulin from rabbits data

A Phase II trial of Thymoglobulin in 72 patients showed significant improvement in acceptance of kidney transplants compared to Atgam horse immunoglobulin. Thymoglobulin reduced rejection episodes by 83 percent. Biopsy-proven rejection was 4.2 percent in patients given the SANG product, compared to 25 percent in the others (p=0.01).

Other end points included event-free survival, with no rejection, death or loss of graft, and this was achieved in 94 percent of patients versus 61 percent who received Atgam (p=0.0005). Only 10.4 percent of Thymoglobulin patients developed CMV disease, compared to 33.3 percent on Atgam (p=0.025). ...